Patents Assigned to WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD
-
Patent number: 11786471Abstract: A complex disintegrant composition for oral solid preparation, comprising a disintegrant and a disintegrating aid, the disintegrant being a hygroscopic expansion type disintegrant, the disintegrating aid being a soluble small molecule substance or a gas-producing type salt. An oral solid preparation, comprising an active ingredient, said complex disintegrant composition, an excipient and a lubricant.Type: GrantFiled: June 27, 2017Date of Patent: October 17, 2023Assignee: WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO. LTD.Inventors: Yaowen Wan, Yongkai Chen, Xian Zeng, Chaodong Wang, Wei Feng
-
Patent number: 11337972Abstract: A pharmaceutical preparation includes a first active component, a second active component and pharmaceutically acceptable excipients. The first active component is at least one selected from the group consisting of a neutral endopeptidase inhibitor and a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, a prodrug and a solvate thereof. The second active component is at least one selected from the group consisting of a compound represented by the following formula (I) or a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, a prodrug and a solvate thereof. The pharmaceutically acceptable excipients include one or more disintegrants and/or one or more fillers.Type: GrantFiled: March 8, 2019Date of Patent: May 24, 2022Assignees: WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD., WUHAN QR PHARMACEUTICALS CO., LTD., WUHAN ZY PHARMACEUTICALS CO., LTD.Inventors: Xiaojing Hu, Lina Qian, Zhichao Zhang, Yuanping Wang, Yongkai Chen, Wei Feng, Wenwen Qi, Chaodong Wang
-
Patent number: 11161803Abstract: The present disclosure belongs to the field of chemical synthesis, and in particular relates to an ammonium carboxylate compound, a crystalline form and an amorphous form, and a preparation method thereof. The present disclosure prepares the compound and the crystalline form I and its single crystal, amorphous form and crystalline form II thereof. The compound, the crystalline forms, the single crystal and the amorphous form can stably exist and exhibit good solid forms, suitable for medicine-making. Furthermore, these products possess high purity and less single impurity. Moreover, the preparation methods of the present disclosure are easy to implement due to the simple processes with mild reaction conditions, and could produce products of high yield and high purity without complex purification steps. Furthermore, the preparation methods may facilitate safety, environmental protection, and industrial production.Type: GrantFiled: April 27, 2018Date of Patent: November 2, 2021Assignee: WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD.Inventors: Bo Zhang, Xiaohua Ding, Dongcheng Dai, Sijun Lei, Xueming Liu, Panpan Duan, Yongkai Chen, Chaodong Wang
-
Patent number: 11096928Abstract: The present invention relates to a pharmaceutical composition comprising: (a) at least one neutral endopeptidase inhibitor or a pharmaceutically acceptable salt or ester thereof, (b) at least one compound represented by formula (I) or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier. Combined administration showed better medicinal effects than separate administration.Type: GrantFiled: September 27, 2017Date of Patent: August 24, 2021Assignee: WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD.Inventors: Chaodong Wang, Yongkai Chen, Liu Hu, Xian Zeng, Daiwu Kang
-
Patent number: 11040958Abstract: The present disclosure provides a triazole antibacterial derivative and a pharmaceutical composition thereof and a use thereof and in particular relates to a compound represented by the following formula (I), and a racemate, a stereoisomer, a tautomer, an oxynitride or a pharmaceutically acceptable salt thereof: The compound of the present disclosure has a desirable water solubility and can be formulated into an injection for use without adding a cosolvent having a potential safety risk (such as hydroxypropyl-?-cyclodextrin, sulfobutylether-?-cyclodextrin, and the like), facilitating drug administration for patients, and greatly improving clinical safety. The drug can be used even by patients with moderate or severe renal impairment, thereby expanding the application scope of the drug.Type: GrantFiled: February 8, 2018Date of Patent: June 22, 2021Assignees: WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD., WUHAN QR PHARMACEUTICALS CO., LTD.Inventors: Hongwei Tang, Jun Lou, Penggao Yu, Li Liu, Anxiao Zheng, Yongkai Chen, Chaodong Wang
-
Patent number: 11013736Abstract: The invention discloses an oral solid preparation containing any one, or a mixture of two or more of crystalline form I, II, III, and IV of the compound represented by formula (A). The oral solid preparation of the present invention disintegrates rapidly, increasing dissolution rate thereof, thereby improving bioavailability. In particular, it is possible to solve the problem that an active material (active ingredient), which is high hygroscopic and becomes sticky after moisture absorption, can not be effectively disintegrated by conventional disintegrants. The present invention further relates to a use of the oral solid preparation in preparing an angiotensin II receptor antagonist or a use thereof in preparing medicine for preventing and/or treating hypertension, chronic heart failure and diabetic nephropathy.Type: GrantFiled: July 28, 2017Date of Patent: May 25, 2021Assignee: WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD.Inventors: Lei Liang, Yongkai Chen, Liu Hu, Wei Feng, Chaodong Wang
-
Patent number: 11008311Abstract: The preparation method for the compound, composition and application thereof in preparing an angiotensin II receptor antagonist or application in preparing medicine for preventing and/or treating hypertension, chronic heart failure and diabetic nephropathy. After entering a human body, when releasing azilsartan, the compound releases hydroxyligustrazine or NO at the same time, thus generating a synergistic effect with azilsartan. The compound therefore has stronger and longer blood pressure lowering effect, more obvious and longer lasting heart rate lowering effect and high safety, and achieves ideal protective effect for heart and kidney functions.Type: GrantFiled: May 19, 2017Date of Patent: May 18, 2021Assignee: WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD.Inventors: Sijun Lei, Xiang Fang, Yongkai Chen, Wei Feng, Chaodong Wang
-
Publication number: 20210052579Abstract: A pharmaceutical preparation includes a first active component, a second active component and pharmaceutically acceptable excipients. The first active component is at least one selected from the group consisting of a neutral endopeptidase inhibitor and a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, a prodrug and a solvate thereof. The second active component is at least one selected from the group consisting of a compound represented by the following formula (I) or a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, a prodrug and a solvate thereof. The pharmaceutically acceptable excipients include one or more disintegrants and/or one or more fillers.Type: ApplicationFiled: March 8, 2019Publication date: February 25, 2021Applicants: Wuhan ll Science and Technology Development Co., Ltd., Wuhan qr Pharmaceuticals Co., Ltd., Wuhan zy Pharmaceuticals Co., Ltd.Inventors: Xiaojing HU, Lina QIAN, Zhichao ZHANG, Yuanping WANG, Yongkai CHEN, Wei FENG, Wenwen QI, Chaodong WANG
-
Patent number: 10611757Abstract: Provided are a preparation method for a crystalline form of the compound represented by formula (A), as well as a method for preparation thereof, a composition thereof, and an application thereof in preparing an angiotensin II receptor antagonist or an application in preparing a drug for preventing and/or treating hypertension, chronic heart failure and diabetic nephropathy.Type: GrantFiled: July 10, 2017Date of Patent: April 7, 2020Assignees: Wuhan LL Science and Technology Development Co., Ltd., Wuhan QR Pharmaceuticals Co., Ltd.Inventors: Sijun Lei, Xiang Fang, Yongkai Chen, Wei Feng, Chaodong Wang
-
Patent number: 10517867Abstract: The present disclosure provides a posaconazole derivative, a pharmaceutical composition and use thereof, which specifically include a compound represented by the following formula (I), a racemate, stereoisomer, tautomer, oxynitride, or a pharmaceutically acceptable salt thereof: The compounds of the present disclosure have strong antifungal activity, high safety, and good water solubility, without the need for the addition of a cosolvent (such as hydroxypropyl-?-cyclodextrin, sulfobutyl ether-?-cyclodextrin, and the like) with potential safety risks. Furthermore, the formulation process of the compound could have less difficulty and less cost, and therefore can be used to prepare improved antifungal drugs.Type: GrantFiled: January 26, 2017Date of Patent: December 31, 2019Assignees: WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD., WUHAN QR PHARMACEUTICALS CO., LTD.Inventors: Jun Lou, Penggao Yu, Li Liu, Hongwei Tang, Anxiao Zheng, Yongkai Chen, Chaodong Wang
-
Publication number: 20190328673Abstract: A complex disintegrant composition for oral solid preparation, comprising a disintegrant and a disintegrating aid, the disintegrant being a hygroscopic expansion type disintegrant, the disintegrating aid being a soluble small molecule substance or a gas-producing type salt. An oral solid preparation, comprising an active ingredient, said complex disintegrant composition, an excipient and a lubricant.Type: ApplicationFiled: June 27, 2017Publication date: October 31, 2019Applicants: Wuhan LL Science and Technology Development Co., Ltd, Wuhan QR Pharmaceuticals Co., LtdInventors: Yaowen WAN, Yongkai CHEN, Xian ZENG, Chaodong WANG, Wei FENG
-
Publication number: 20190177312Abstract: Provided are a preparation method for a crystalline form of the compound represented by formula (A), as well as a method for preparation thereof, a composition thereof, and an application thereof in preparing an angiotensin II receptor antagonist or an application in preparing a drug for preventing and/or treating hypertension, chronic heart failure and diabetic nephropathy.Type: ApplicationFiled: July 10, 2017Publication date: June 13, 2019Applicants: Wuhan LL Science and Technology Development Co., Ltd., Wuhan QR Pharmaceuticals Co., Ltd.Inventors: Sijun LEI, Xiang FANG, Yongkai CHEN, Wei FENG, Chaodong WANG
-
Patent number: 9708306Abstract: The invention belongs to the technical field of pharmaceutical chemistry, and particularly pertains to benzimidazole derivatives, and preparation process and pharmaceutical uses thereof. Benzimidazole derivatives include Ligustrazine and NO donor derivatives. The kind of the compounds can rapidly release Ligustrazine or No in vivo, so that they can produce effective synergetic effects with Azilsartan, to enhance the anti-hypertension effect, and reduce adverse effects, and the released Ligustrazine can produce ideal protection to patients' livers and kidneys, thereby filling blanks in the prior art.Type: GrantFiled: March 18, 2015Date of Patent: July 18, 2017Assignees: WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD, WUHAN QR PHARMACEUTICALS CO., LTDInventors: Jian Ge, Jianyi Ma, Guangya Xiang, Wei Wang, Chaodong Wang